	US 12,480,163 B2
	Compositions and methods for identification assessment, prevention, and treatment of Ewing sarcoma using TP53 dependency biomarkers and modulators
Kimberly Stegmaier, Jamaica Plain, MA (US)
Assigned to Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Appl. No. 17/260,824
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US)
PCT Filed Jul. 17, 2019, PCT No. PCT/US2019/042110 § 371(c)(1), (2) Date Jan. 15, 2021, PCT Pub. No. WO2020/018611, PCT Pub. Date Jan. 23, 2020.
Claims priority of provisional application 62/699,970, filed on Jul. 18, 2018.
Prior Publication US 2021/0324478 A1, Oct. 21, 2021
Int. Cl. C12Q 1/6886 (2018.01); A61K 38/12 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01); G01N 33/50 (2006.01)

CPC C12Q 1/6886 (2013.01) [A61K 38/12 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); G01N 33/5011 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/158 (2013.01)]

18 Claims

1. A method of treating a subject afflicted with Ewing sarcoma, wherein cancer cells of the Ewing sarcoma encode intact tumor-suppressor 53 (p53), comprising administering to the subject i) a mouse double minute 2 (MDM2) inhibitor, wherein the MDM2 inhibitor is ATSP-7041, and ii) a ubiquitin specific peptidase 7 (USP7) inhibitor or a protein phosphatase, Mg2+/Mn2+-dependent 1D (PPM1D) inhibitor, wherein the USP7 inhibitor is P5091 or the PPM1D inhibitor is GSK2830371, thereby treating the subject afflicted with Ewing sarcoma.